EPFL scientists have now analyzed the genomes of more than 200
patients with follicular lymphoma, and they discover that a gene, Sestrin1, is frequently missing or malfunctioning in FL patients.
Eleven patients experienced complete responses to the therapy, and two had partial responses, including a 100 percent response rate (six complete responses and one partial response) among
the patients with follicular lymphoma who received the therapy.